Anavex Life Sciences Corp (AVXL)

[JB3729]

Patent application 13/940352 update -

This is the application for Anavex Plus (A2-73 and donepezil combo) and A2-73 combined with other drugs.

As of 8/1, it looks like Anavex has dropped the other combos from the application.

Up until 6/28, the Examiner had argued that donepezil was only additive to A2-73 and described the combo as obviousness. Anavex argued that the combo was synergistic. On 6/28 the examiner seemed to concede that the A2-73/donepezil combo was synergistic.

On 8/1, Anavex filed - Applicant agrees with the Examiner's Action that Fig. 5 demonstrates the synergy of A2-73 and donepezil.

Applicant believes that this application is in condition for allowance, which is respectfully requested.

IMO, it looks good for the patent allowance!

I consider this a big deal because we don't know what arm of the Phase 3 trial will show the best results, or, even if there will be an A2-73 alone arm. In Phase 2a, it is possible that the group being dosed with A2-73 and donepezil has a few duds in it which would have a big impact on the data, with such a small number of patients. We'll see.